SI3083625T1 - Pyrimidopyrimidinones, useful as Wee-1 kinase inhibitors - Google Patents

Pyrimidopyrimidinones, useful as Wee-1 kinase inhibitors Download PDF

Info

Publication number
SI3083625T1
SI3083625T1 SI201430580T SI201430580T SI3083625T1 SI 3083625 T1 SI3083625 T1 SI 3083625T1 SI 201430580 T SI201430580 T SI 201430580T SI 201430580 T SI201430580 T SI 201430580T SI 3083625 T1 SI3083625 T1 SI 3083625T1
Authority
SI
Slovenia
Prior art keywords
methyl
amino
dihydropyrimido
pyrimidin
phenyl
Prior art date
Application number
SI201430580T
Other languages
English (en)
Slovenian (sl)
Inventor
Timothy Harrison
Graham Trevitt
Peter Robin Hewitt
Colin Roderick O'dowd
Frank Burkamp
Andrew John Wilkinson
Steven D. Shepherd
Hugues Miel
Original Assignee
Almac Discovery Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Discovery Limited filed Critical Almac Discovery Limited
Publication of SI3083625T1 publication Critical patent/SI3083625T1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201430580T 2013-12-19 2014-12-19 Pyrimidopyrimidinones, useful as Wee-1 kinase inhibitors SI3083625T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1322602.2A GB201322602D0 (en) 2013-12-19 2013-12-19 Pharmaceutical compounds
EP14815843.9A EP3083625B1 (en) 2013-12-19 2014-12-19 Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
PCT/GB2014/053793 WO2015092431A1 (en) 2013-12-19 2014-12-19 Pyrimidopyrimidinones useful as wee-1 kinase inhibitors

Publications (1)

Publication Number Publication Date
SI3083625T1 true SI3083625T1 (en) 2018-03-30

Family

ID=50071157

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201430580T SI3083625T1 (en) 2013-12-19 2014-12-19 Pyrimidopyrimidinones, useful as Wee-1 kinase inhibitors

Country Status (28)

Country Link
US (1) US9850247B2 (enExample)
EP (1) EP3083625B1 (enExample)
JP (1) JP6437559B2 (enExample)
KR (1) KR102405462B1 (enExample)
CN (1) CN105829315B (enExample)
AU (1) AU2014369457B2 (enExample)
BR (1) BR112016014151B1 (enExample)
CA (1) CA2933755C (enExample)
CY (1) CY1120035T1 (enExample)
DK (1) DK3083625T3 (enExample)
ES (1) ES2650013T3 (enExample)
GB (1) GB201322602D0 (enExample)
HR (1) HRP20180080T1 (enExample)
HU (1) HUE037908T2 (enExample)
IL (1) IL245672B (enExample)
LT (1) LT3083625T (enExample)
MX (1) MX371108B (enExample)
NO (1) NO3083625T3 (enExample)
NZ (1) NZ720178A (enExample)
PL (1) PL3083625T3 (enExample)
PT (1) PT3083625T (enExample)
RS (1) RS56731B1 (enExample)
RU (1) RU2691105C1 (enExample)
SG (1) SG11201603814TA (enExample)
SI (1) SI3083625T1 (enExample)
SM (1) SMT201800020T1 (enExample)
WO (1) WO2015092431A1 (enExample)
ZA (1) ZA201603337B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016168992A1 (en) * 2015-04-21 2016-10-27 Ruijin Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine Preparation and use of novel protein kinase inhibitors
EP3368538B1 (en) 2015-11-01 2021-09-01 The Regents of The University of Colorado, A Body Corporate Wee 1 kinase inhibitors and methods of making and using the same
WO2018090939A1 (zh) * 2016-11-16 2018-05-24 上海瑛派药业有限公司 8,9-二氢咪唑[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮类化合物
US10954216B2 (en) 2016-12-27 2021-03-23 Riken BMP-signal-inhibiting compound
CN110198943B (zh) * 2017-01-23 2021-04-16 石家庄智康弘仁新药开发有限公司 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
GB201703881D0 (en) * 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
US20200108074A1 (en) 2017-03-31 2020-04-09 Seattle Genetics, Inc. Combinations of chk1- and wee1- inhibitors
US11345710B2 (en) 2017-07-10 2022-05-31 Impact Therapeutics (Shanghai), Inc Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof
CN109422754A (zh) * 2017-08-24 2019-03-05 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
CA3078945A1 (en) 2017-10-09 2019-04-18 Nuvation Bo Inc. Heterocyclic compounds and uses thereof
WO2019074979A1 (en) 2017-10-09 2019-04-18 Girafpharma, Llc HETEROCYCLIC COMPOUNDS AND USES THEREOF
CN117534673A (zh) 2017-11-01 2024-02-09 无锡智康弘义生物科技有限公司 作为Wee1抑制剂的大环类化合物及其应用
EP3758706A4 (en) * 2018-02-28 2021-11-24 The Regents Of The University Of Colorado WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THEREOF
CN112771049B (zh) * 2018-09-27 2024-01-26 贝达药业股份有限公司 Fgfr4抑制剂及其应用
CN112955454A (zh) 2018-10-26 2021-06-11 石家庄智康弘仁新药开发有限公司 作为Wee1抑制剂的嘧啶并吡唑酮类衍生物及其应用
AU2019413360B2 (en) 2018-12-28 2025-05-22 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US20220194960A1 (en) 2019-03-22 2022-06-23 Shouyao Holdings (beijing) Co., Ltd. Wee1 inhibitor and preparation and use thereof
MX2021012418A (es) 2019-04-09 2021-11-12 Nuvation Bio Inc Compuestos heterociclicos y sus usos.
EP3952878A4 (en) * 2019-04-09 2023-01-04 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND THEIR USES
EP3952879A4 (en) * 2019-04-09 2023-01-04 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND THEIR USES
WO2020221358A1 (zh) 2019-04-30 2020-11-05 石家庄智康弘仁新药开发有限公司 Wee1抑制剂化合物的晶型及其应用
CN112142763B (zh) * 2019-06-28 2024-01-26 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
US20230159540A1 (en) 2020-06-17 2023-05-25 Wigen Biomedicine Technology (shanghai) Co., Ltd. PYRAZOLO[3,4-d]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR
EP4221710A4 (en) * 2020-10-01 2024-09-18 University of Washington DRUG-LIKE MOLECULES AND METHODS FOR THERAPEUTIC TARGETING OF MICRORNA-21
PH12023551406A1 (en) * 2020-12-18 2024-01-22 Glaxosmithkline Ip Dev Ltd Chemical compounds useful for inhibiting nav1 .8 voltage-gated sodium channels and treating nav1 .8 mediated diseases
EP4263540A1 (en) * 2020-12-18 2023-10-25 GlaxoSmithKline Intellectual Property Development Limited Nitrogen containing 2,3-dihydroquinazolinone compounds as nav1.8 inhibitors
CN117222648A (zh) 2021-04-30 2023-12-12 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的稠环化合物及其制备方法和用途
US12161722B2 (en) 2021-06-25 2024-12-10 Korea Research Institute Of Chemical Technology Bifunctional heterocyclic compound having BTK degradation function via ubiquitin proteasome pathway, and use thereof
CN116462687B (zh) 2022-01-18 2025-01-07 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
CN116836184B (zh) * 2022-03-25 2025-07-25 药雅科技(上海)有限公司 Wee1激酶抑制剂的制备及其应用
WO2023217201A2 (zh) * 2022-05-10 2023-11-16 杭州德睿智药科技有限公司 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用
CN117402162A (zh) 2022-07-13 2024-01-16 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
WO2025101691A1 (en) 2023-11-08 2025-05-15 Exelixis, Inc. Methods for treating cancer using compounds that inhibit pkmyt1

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
RU2006136082A (ru) 2004-03-15 2008-04-27 Ф.Хоффманн-Ля Рош Аг (Ch) Новые производныедихлорфенилпиридо[2,3]пиримидина, их получение и применение в качестве фармацевтических агентов
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
PE20080695A1 (es) 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
JP5411847B2 (ja) 2007-04-25 2014-02-12 Msd株式会社 Weelキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形
HRP20161536T1 (hr) 2007-06-15 2016-12-30 Msd K.K. Derivat bicikloanilina
JPWO2009054332A1 (ja) * 2007-10-23 2011-03-03 萬有製薬株式会社 ピリドン置換ジヒドロピラゾロピリミジノン誘導体
EP2376494A4 (en) * 2008-12-12 2012-07-11 Msd Kk DIHYDROPYRIMIDOPYRIMIDINDERIVATE
EP2376493B1 (en) 2008-12-12 2016-10-05 Msd K.K. Dihydropyrimidopyrimidine derivative
ES2559224T3 (es) * 2010-12-06 2016-02-11 Glaxo Group Limited Compuestos de pirimidinona para uso en el tratamiento de enfermedades o condiciones mediadas por Lp-PLA2
AR084515A1 (es) 2010-12-22 2013-05-22 Merz Pharma Gmbh & Co Kgaa Derivados heterociclicos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades asociadas al sistema nervioso central tales como parkinson y alzheimer, entre otras
TWI532742B (zh) * 2011-02-28 2016-05-11 艾伯維有限公司 激酶之三環抑制劑
EP2731953A1 (en) 2011-07-15 2014-05-21 Abbvie Inc. Tricyclic inhibitors of kinases useful for the treatment of proliferative diseases
WO2013013031A1 (en) * 2011-07-19 2013-01-24 Abbvie Inc. Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase
CA2851640A1 (en) 2011-10-20 2013-04-25 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
JP2015511245A (ja) * 2012-02-23 2015-04-16 アッヴィ・インコーポレイテッド ピリドピリミジノン系キナーゼ阻害薬
CN102816164A (zh) * 2012-08-31 2012-12-12 北京理工大学 一种合成7-氨基-2,3-二氢嘧啶[4,5-d]嘧啶-4(1H)-酮的方法

Also Published As

Publication number Publication date
KR20160098499A (ko) 2016-08-18
US20160318936A1 (en) 2016-11-03
MX2016007801A (es) 2016-09-07
GB201322602D0 (en) 2014-02-05
EP3083625B1 (en) 2017-11-01
US9850247B2 (en) 2017-12-26
JP6437559B2 (ja) 2018-12-12
WO2015092431A1 (en) 2015-06-25
BR112016014151B1 (pt) 2023-01-17
RS56731B1 (sr) 2018-03-30
ZA201603337B (en) 2018-07-25
JP2017500335A (ja) 2017-01-05
AU2014369457A1 (en) 2016-06-09
BR112016014151A2 (enExample) 2017-08-08
AU2014369457B2 (en) 2018-08-09
CN105829315A (zh) 2016-08-03
PT3083625T (pt) 2018-02-06
IL245672A0 (en) 2016-06-30
LT3083625T (lt) 2017-12-27
SMT201800020T1 (it) 2018-05-02
DK3083625T3 (en) 2017-12-18
CN105829315B (zh) 2019-03-08
RU2016123363A (ru) 2018-01-25
NO3083625T3 (enExample) 2018-03-31
CY1120035T1 (el) 2018-12-12
MX371108B (es) 2020-01-17
HUE037908T2 (hu) 2018-09-28
KR102405462B1 (ko) 2022-06-03
HRP20180080T1 (hr) 2018-03-09
IL245672B (en) 2021-10-31
ES2650013T3 (es) 2018-01-16
EP3083625A1 (en) 2016-10-26
CA2933755A1 (en) 2015-06-25
SG11201603814TA (en) 2016-07-28
PL3083625T3 (pl) 2018-03-30
CA2933755C (en) 2023-01-31
NZ720178A (en) 2022-05-27
RU2691105C1 (ru) 2019-06-11

Similar Documents

Publication Publication Date Title
SI3083625T1 (en) Pyrimidopyrimidinones, useful as Wee-1 kinase inhibitors
JP2019535664A5 (enExample)
RU2473549C2 (ru) Пиримидиновые соединения, композиции и способы применения
CN117651700A (zh) 2-氨基苯并噻唑化合物及使用方法
RU2019115115A (ru) Производные пиперидина в качестве ингибиторов убиквитин-специфической протеазы 7
JP2024532733A (ja) 複素環式化合物及び使用方法
JP2024532735A (ja) 複素環式化合物及び使用方法
JP2016525092A5 (enExample)
RU2015148189A (ru) ПРОИЗВОДНЫЕ 2-АМИДОПИРИДО[4, 3-d]ПИРИМИДИН-5-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ WEE-1
HRP20231730T1 (hr) Fenilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene
JP2025508702A (ja) キナゾリン化合物、及び変異krasタンパク質の阻害剤としてのその使用
RU2018138471A (ru) Гетероциклические соединения в качестве ингибиторов киназы RET
JP2011511034A5 (enExample)
RU2019120986A (ru) Фармацевтическая комбинация, содержащая ингибитор alk и ингибитор shp2
FI3436461T3 (fi) Pyrrolotriatsiiniyhdisteitä tam-inhibiittoreina
RU2017141077A (ru) Ингибитор некоторых протеинкиназ
JP2015508075A5 (enExample)
JP6695353B2 (ja) Fgfr4阻害剤としてのホルミル化n−複素環式誘導体
RU2014151004A (ru) Пирролопиримидоновые и пирролопиридоновые ингибиторы танкиразы
AU2021370660A1 (en) Heterocyclic spiro compounds and methods of use
JPWO2020231806A5 (enExample)
RU2016151315A (ru) Некоторые ингибиторы протеинкиназы
JP2016537384A5 (enExample)
JP2025535046A (ja) Kras g12c変異タンパク質の複素環阻害剤及びその使用
RU2014109748A (ru) Морфолино-замещенные производные бициклических пиримидинмочевины или карбамата в качестве ингибиторов mtor